Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15099527 | 0.93 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1ADORA2AADORA1PDE10A | |
| SCHEMBL902048 | 0.92 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1ADORA2AADORA1NAMPT | |
| SCHEMBL901504 | 0.92 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ADORA2ANAMPT | |
| SCHEMBL904245 | 0.90 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ADORA2AADORA1BACE1 | |
| SCHEMBL901437 | 0.89 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1ADORA2AADORA1PDE10A | |
| Hydrochloric Acid SCHEMBL902804 | 0.88 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1ADORA2AADORA1PDE10A | |
| SCHEMBL15091268 | 0.88 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ADORA2AADORA1BACE1 | |
| SCHEMBL902136 | 0.86 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1ADORA2AADORA1BACE1 | |
| SCHEMBL15099534 | 0.85 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1ADORA2AADORA1 | |
| SCHEMBL904088 | 0.84 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ADORA2AADORA1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | claimed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | claimed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791129-B2 | Phenylquinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2621919-A1 | PHENYLQUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041435-A1 | PHENYLQUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178443-A1 | PHENYLQUINAZOLINE DERIVATIVES | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885ADORA2A 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.